Last updated: September 21, 2026
Ceritinib, marketed by Novartis as Zykadia, is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for ALK-positive metastatic non-small-cell lung cancer (NSCLC). Its commercial trajectory peaked after first-line approval but declined as physicians shifted toward alectinib and lorlatinib, while crizotinib became available at lower cost. Ceritinib remains commercially relevant in selected patients, but its market is mature, competitively pressured, and approaching generic-entry risk.
What is ceritinib and how is it used?
Ceritinib is a small-molecule ALK tyrosine kinase inhibitor. It also inhibits IGF-1R and ROS1 at clinically relevant concentrations, although its commercial positioning is centered on ALK-positive NSCLC.
The U.S. Food and Drug Administration approved Zykadia in April 2014 under the accelerated approval pathway for patients with metastatic ALK-positive NSCLC who had progressed on or were intolerant to crizotinib. FDA later expanded approval to first-line treatment in May 2017 and approved the 450 mg dose with food to improve tolerability while preserving exposure.[1]
Key product facts
| Category |
Ceritinib |
| Brand |
Zykadia |
| Active ingredient |
Ceritinib |
| Manufacturer |
Novartis |
| Drug class |
ALK tyrosine kinase inhibitor |
| Initial FDA approval |
April 29, 2014 |
| First-line FDA approval |
May 26, 2017 |
| Main indication |
Metastatic ALK-positive NSCLC |
| Dosage forms |
150 mg and 180 mg capsules |
| Standard current dose |
450 mg once daily with food |
| Regulatory pathway |
New drug application, with initial accelerated approval |
| Product type |
Small molecule |
| Biosimilar pathway |
Not applicable |
Ceritinib’s initial 750 mg fasting regimen created substantial gastrointestinal toxicity and treatment-management challenges. The lower 450 mg dose taken with food reduced gastrointestinal adverse events and became the preferred regimen.[2]
How has the ceritinib market changed?
Ceritinib entered a market dominated by crizotinib and later faced competition from more selective or better-tolerated ALK inhibitors. The most important competitive shift was the movement of alectinib into the preferred first-line position after superior progression-free survival and central nervous system activity were demonstrated in untreated ALK-positive NSCLC.[3]
Lorlatinib added further pressure through strong intracranial activity and broad coverage of resistance mutations. Brigatinib competes in both treatment-naive and previously treated settings. Crizotinib remains relevant through physician familiarity and lower pricing after loss of exclusivity.
Competitive positioning in ALK-positive NSCLC
| Drug |
Company |
Principal commercial strength |
Principal pressure on ceritinib |
| Alectinib |
Roche |
Strong first-line efficacy and CNS penetration |
Preferred first-line competitor |
| Brigatinib |
Takeda |
First-line efficacy and activity after crizotinib |
Competes across treatment lines |
| Lorlatinib |
Pfizer |
CNS activity and resistance-mutation coverage |
Premium next-generation competitor |
| Crizotinib |
Pfizer and generics |
Established use and lower cost |
Generic pricing pressure |
| Ceritinib |
Novartis |
Activity after prior ALK therapy and oral administration |
Toxicity, food requirement, later-line positioning |
The CROWN, ALEX, and ALTA-1L studies reshaped treatment sequencing. Alectinib and lorlatinib gained preference in many treatment guidelines, reducing ceritinib’s role in untreated patients.[3-5]
What is the financial trajectory of Zykadia?
Novartis does not consistently disclose Zykadia as a separately reported growth product in its principal financial reporting. Public company disclosures and oncology-product reporting indicate a clear decline from the late 2010s peak.
Approximate global sales were:
| Year |
Estimated Zykadia sales |
Market interpretation |
| 2015 |
About $90 million |
Early commercial expansion |
| 2016 |
About $180 million |
Growth in post-crizotinib use |
| 2017 |
About $260 million |
First-line label expansion |
| 2018 |
About $280 million |
Approximate commercial peak |
| 2019 |
About $220 million |
Competitive displacement begins |
| 2020 |
About $180 million |
Continued decline |
| 2021 |
About $140 million |
Alectinib and brigatinib pressure |
| 2022 |
About $100 million |
Mature-product contraction |
| 2023 |
Below $100 million |
Later-line and regional demand |
The figures are directional estimates based on Novartis annual reports, product sales disclosures, and market reporting. Novartis has increasingly grouped mature oncology products within broader reporting categories, limiting product-level visibility.[6]
What drove the revenue decline?
Four factors explain most of the decline:
- First-line treatment shifted toward alectinib and lorlatinib.
- Crizotinib generic entry reduced the price ceiling for earlier-line therapy.
- Ceritinib’s gastrointestinal toxicity remained a prescribing disadvantage.
- Ceritinib became more dependent on later-line use and regional markets.
The 2017 first-line approval briefly expanded the addressable market, but that benefit was offset by more effective competitor launches and changing treatment guidelines.
When does ceritinib lose exclusivity?
Ceritinib has already lost U.S. regulatory exclusivity, but patent protection is more important for determining generic-launch timing.
The FDA’s five-year new chemical entity exclusivity expired in 2019. That exclusivity blocked submission of an ANDA for the first five years after approval, subject to statutory exceptions. It did not prevent other regulatory pathways after that period.
Ceritinib exclusivity timeline
| Event |
Date |
| U.S. FDA approval |
April 29, 2014 |
| NCE exclusivity expiration |
April 29, 2019 |
| First-line approval |
May 26, 2017 |
| 450 mg with food approval |
May 26, 2017 |
| Core U.S. patent term |
Approximately 2027, subject to patent-term adjustment and listing status |
| Likely generic-risk window |
Before or around 2027, depending on certifications and litigation |
The principal U.S. compound patent associated with ceritinib is U.S. Patent No. 8,337,880. Public patent records identify Novartis-related entities as the patent owners or applicants and indicate a base term extending into 2027, subject to patent-term adjustment and any relevant patent-term extension.[7]
A definitive launch date depends on the active Orange Book listings, the expiration dates reported by FDA, any pediatric exclusivity, patent-term adjustment, Paragraph IV litigation, and the settlement terms of any later-filed ANDA disputes.
What patents protect ceritinib?
Ceritinib protection has historically included compound, formulation, dosage, and treatment-related patent claims. The compound patent is the most important barrier because it can block products containing the active ingredient regardless of the specific label.
Principal patent categories
| Patent category |
Commercial purpose |
Generic-entry relevance |
| Compound patent |
Protects ceritinib and related chemical structures |
Highest potential blocking value |
| Solid-state or polymorph patent |
Protects selected crystalline forms |
May constrain formulation design |
| Pharmaceutical composition patent |
Protects drug-containing compositions |
Relevant where the ANDA uses a claimed composition |
| Dosing patent |
Protects administration with food or specific dosing regimens |
Usually less effective against a broad ANDA challenge |
| Method-of-use patent |
Protects ALK-positive cancer treatment |
More vulnerable to skinny-label strategies |
The U.S. Orange Book should be treated as the controlling source for active listed patents and expiration dates at the time of an ANDA filing.[8] Patent-family protection may continue in Europe, Japan, China, Canada, and other markets even where U.S. protection is approaching expiry.
How strong is the ceritinib patent estate?
The estate is moderate rather than highly durable.
The compound patent provides the strongest protection, but its expected U.S. expiration is close enough to create a defined generic-entry horizon. Method-of-use and dosing patents are more vulnerable to non-infringing label design, treatment-sequencing arguments, or skinny-label submissions. Formulation patents can delay some generic products but generally do not provide the same protection as a composition-of-matter patent.
Ceritinib is also a small molecule with a relatively conventional oral capsule presentation. It does not have the manufacturing complexity associated with biologics, antibody-drug conjugates, or long-acting injectable products.
What is the Orange Book status of Zykadia?
Zykadia is listed in the FDA Orange Book as an approved prescription drug product. The Orange Book identifies approved strengths and any patents submitted by the NDA holder for listing.[8]
The commercial risk is determined by three issues:
- Whether the compound patent remains listed and enforceable.
- Whether any formulation or method-of-use patent remains active.
- Whether an ANDA applicant files a Paragraph IV certification against those patents.
An Orange Book listing does not guarantee a patent owner will prevent generic entry. It creates the statutory framework for notice, litigation, and a potential 30-month stay.
Which companies are challenging ceritinib patents?
Publicly visible market activity has not produced a major, widely reported ceritinib patent settlement comparable with the high-profile settlements associated with large cardiovascular, diabetes, or immunology products.
The likely generic challengers are established generic manufacturers with oncology portfolios, including companies such as Teva, Sandoz, Dr. Reddy’s Laboratories, Sun Pharma, Viatris, and Hikma. A specific company should be treated as an active challenger only after an ANDA filing, Paragraph IV notice, district court complaint, or FDA tentative approval becomes public.
What does a Paragraph IV challenge mean for ceritinib?
A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the NDA holder files suit within 45 days of receiving notice, FDA approval may be subject to a 30-month stay, unless the litigation is resolved earlier or the stay is modified.[9]
The first eligible ANDA applicant may receive 180 days of generic exclusivity if it satisfies the statutory requirements. That period can materially affect the speed and price impact of generic entry.
Is there biosimilar risk for ceritinib?
Ceritinib has no biosimilar risk because it is a chemically synthesized small molecule. The relevant pathway is an abbreviated new drug application, not a 351(k) biosimilar application.
Generic risk still depends on:
- Bioequivalence requirements.
- Capsule formulation.
- Food-effect studies.
- Label carve-outs.
- Patent certifications.
- Manufacturing capacity.
- Ability to support oncology distribution.
The food requirement may add testing and labeling complexity, but it is unlikely to create a durable manufacturing barrier. Generics can generally reproduce small-molecule capsules through conventional pharmaceutical manufacturing.
What generic launch scenarios exist for ceritinib?
Three launch scenarios are commercially plausible.
Scenario 1: At-risk launch before final patent expiry
A generic company launches after winning or settling Paragraph IV litigation before the principal patent expires. This would produce the fastest price erosion but expose the manufacturer to damages if the patent is later upheld.
Scenario 2: First launch near patent expiry
The generic launches after the main compound patent expires or after a settlement permits entry. This is the most likely base case for orderly market entry.
Scenario 3: Delayed or limited entry
A formulation or use patent, manufacturing problem, or litigation settlement delays one or more products. In that case, limited generic competition may preserve part of Zykadia’s pricing for a period, but the product would still face gradual erosion from declining branded demand.
For a mature oncology product, the first generic competitor can reduce net pricing sharply. A second and third entrant generally accelerate the decline, although the magnitude depends on oncology-channel purchasing, payer contracts, and the number of approved suppliers.
What regulatory factors affect ceritinib demand?
FDA approval remains limited to ALK-positive metastatic NSCLC, identified through an FDA-approved diagnostic test. The clinical market is therefore determined by:
- The number of newly diagnosed and recurrent NSCLC patients.
- ALK rearrangement prevalence, generally around 3% to 7% of NSCLC cases.
- Testing rates using next-generation sequencing and fluorescence in situ hybridization.
- Treatment-line positioning.
- Duration of therapy.
- Competitive guideline recommendations.
The target population is relatively small but has historically supported premium pricing because ALK-positive disease is a molecularly defined subgroup and patients can remain on treatment for extended periods. The market has matured as broad molecular testing became standard and more patients receive a next-generation ALK inhibitor before ceritinib.
What licensing deals affect ceritinib?
Ceritinib originated from Novartis’s oncology research and is commercially controlled by Novartis. No major external licensing transaction currently defines the product’s market position in the way that licensing deals shape some partnered oncology products.
Novartis has maintained worldwide commercial responsibility for Zykadia. Regional commercialization arrangements, distribution agreements, or local generic licenses may exist in individual jurisdictions, but they do not materially change the global strategic profile.
How does ceritinib compare with alectinib and lorlatinib?
| Factor |
Ceritinib |
Alectinib |
Lorlatinib |
| First-line role |
Reduced by competition |
Strong |
Strong |
| CNS activity |
Clinically meaningful |
Strong |
Very strong |
| Gastrointestinal tolerability |
Less favorable |
Generally more favorable |
Different neurologic and metabolic risks |
| Food administration |
Required for current 450 mg regimen |
No comparable food constraint |
No comparable food constraint |
| Patent outlook |
Mature, approaching generic risk |
Later-life branded protection |
Later-life branded protection |
| Commercial momentum |
Declining |
Stronger |
Strong in selected settings |
| Main opportunity |
Later-line or selected intolerant patients |
Broad first-line treatment |
CNS disease and resistance mutations |
Ceritinib is unlikely to regain broad first-line leadership without new clinical data, a meaningful price advantage, or a differentiated combination strategy. Its best commercial defense is a lower-cost branded position before generic entry and continued use in patients who need an alternative ALK inhibitor.
What is the geographic coverage of ceritinib patents?
Ceritinib patent families have been filed across major pharmaceutical markets, including the United States, Europe, Japan, China, Canada, and other jurisdictions. Expiry dates differ because national patent applications, patent-term adjustments, supplementary protection certificates, and regulatory delays vary by country.
European protection may extend beyond the U.S. base term where a supplementary protection certificate was granted. The commercial value of such protection depends on national reimbursement, generic-registration timing, and whether Novartis continues active promotion.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are limited compared with biologic drugs. Ceritinib requires controlled synthesis, impurity management, solid-state control, capsule production, and compliance with current good manufacturing practices. These requirements are manageable for established generic manufacturers.
The more significant barriers are regulatory and legal:
- Demonstrating bioequivalence under fed conditions.
- Establishing acceptable impurity profiles.
- Avoiding protected polymorph or composition claims.
- Defending Paragraph IV certifications.
- Securing oncology distribution and reimbursement access.
The product’s manufacturing profile supports eventual multi-source generic competition rather than a long period of single-supplier protection.
What is the investment outlook for ceritinib?
Ceritinib is a declining mature oncology asset rather than a growth product. Its remaining value depends on the duration of branded demand, the strength of any surviving patent claims, and the timing of generic entry.
Commercial outlook
| Driver |
Direction |
Effect |
| First-line competition |
Negative |
Reduces prescription share |
| Crizotinib generic pricing |
Negative |
Lowers class pricing |
| Later-line use |
Supportive |
Preserves residual demand |
| ALK testing |
Supportive |
Expands diagnosis of eligible patients |
| Compound-patent expiry |
Negative |
Creates generic risk |
| Manufacturing complexity |
Negative for exclusivity |
Supports generic replication |
| Novartis promotion |
Limited |
Mature products receive less commercial investment |
Revenue exposure is modest relative to Novartis’s major oncology franchises. The product is unlikely to produce meaningful growth, but it can retain residual cash flow in markets where generic competition is delayed or reimbursement remains favorable.
Key Takeaways
- Ceritinib is a mature ALK inhibitor with declining global revenue.
- Zykadia sales likely peaked near $280 million in 2018 and fell below $100 million by 2023.
- Alectinib and lorlatinib displaced ceritinib in much of the first-line market.
- FDA NCE exclusivity expired in 2019.
- The principal U.S. compound patent is expected to expire around 2027, subject to patent-term adjustment and current Orange Book status.
- Ceritinib faces generic, not biosimilar, competition.
- The strongest remaining protection is the compound patent; dosing, formulation, and method-of-use claims are less durable.
- No major publicly reported Paragraph IV settlement currently defines the product’s competitive outlook.
- Generic entry is likely to cause substantial price erosion because ceritinib has a conventional small-molecule capsule and manageable manufacturing requirements.
- The asset’s residual value lies in later-line treatment, regional markets, and any period before broad generic competition.
Frequently Asked Questions
Is ceritinib still commercially important?
Ceritinib remains an approved treatment for ALK-positive metastatic NSCLC, but it is no longer a leading growth product. Its use is concentrated in later-line or selected-patient settings.
Will ceritinib become generic?
Generic ceritinib is commercially likely after resolution or expiration of the principal U.S. patent barriers. The timing depends on ANDA filings, Paragraph IV litigation, and settlement terms.
Does ceritinib have a biosimilar?
No. Ceritinib is a small-molecule drug, so competitors will seek approval through the ANDA generic pathway rather than the biosimilar pathway.
Which ALK inhibitor is the main competitor to ceritinib?
Alectinib is the principal first-line competitor in many treatment settings. Lorlatinib is also important, particularly where central nervous system activity or resistance-mutation coverage is a priority.
What is the biggest weakness of the ceritinib patent estate?
The principal weakness is the approaching expiry of the compound patent combined with the limited blocking power of narrower dosing and method-of-use claims. Conventional small-molecule manufacturing also makes eventual generic replication feasible.
References
- U.S. Food and Drug Administration. (2014). FDA approves Zykadia for late-stage lung cancer.
- U.S. Food and Drug Administration. (2017). FDA approves new dosing regimen for Zykadia and expands indication for ALK-positive metastatic NSCLC.
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W., et al. (2017). Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 377(9), 829-838.
- Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Lee, J. S., et al. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 379(21), 2027-2039.
- Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., et al. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. New England Journal of Medicine, 383(21), 2018-2029.
- Novartis AG. (2015-2023). Annual report and full-year financial results.
- U.S. Patent No. 8,337,880. (2012). 2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl derivatives as ALK inhibitors.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV patent certifications.
